Lopinavir/ritonavir

AHF Praises Colombia's Stand for Accessible HIV Treatment

Retrieved on: 
Friday, October 6, 2023
Infectious Diseases, LGBTQ+, Public Policy, Government, Biotechnology, AIDS, Pharmaceutical, Consumer, Health, Other Policy Issues, ViiV Healthcare, Pan American Health Organization, Lopinavir/ritonavir, Drug resistance, AIDS Healthcare Foundation, AHF, Travel, HIV, Medicine, Laboratory, Abbott Laboratories, Abbott, Refugee, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) supports and applauds the Colombian government’s decision to utilize a compulsory license to import cheaper generic versions of ViiV Healthcare’s HIV treatment dolutegravir.

Key Points: 
  • AIDS Healthcare Foundation (AHF) supports and applauds the Colombian government’s decision to utilize a compulsory license to import cheaper generic versions of ViiV Healthcare’s HIV treatment dolutegravir.
  • The country spends 50 times more on the brand-name drug than the Pan American Health Organization pays for a generic version.
  • AHF opened a clinic in Cúcuta, Colombia , in September 2018 at a critical border crossing with Venezuela to support people living with HIV among the thousands of refugees fleeing the country.
  • Without reliable access to antiretroviral therapy, Venezuelans living with HIV risk dying or developing drug resistance due to treatment interruptions in their home country.

3T Biosciences Announces Appointment of John Leonard, M.D. to its Board of Directors

Retrieved on: 
Tuesday, October 25, 2022
SAN, Lopinavir/ritonavir, TCR, Therapy, Growth, Science, IQVIA, Lightspeed Venture Partners, Patient, Research, Protease inhibitor (pharmacology), Multimedia, Internal medicine, D, Technology, AIDS, R, HIV, National, CEO, Immunotherapy, CRISPR, Adalimumab, Leadership, Stanford University, Ritonavir, Degenerative disease, Johns Hopkins School of Medicine, Abbott, Pharmaceutical industry, Vaccine, AbbVie, Intellia Therapeutics

SAN FRANCISCO, Calif., Oct. 25, 2022 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of John Leonard, M.D. to its board of directors.

Key Points: 
  • Prior to Intellia, he served as chief scientific officer and global vice president of research and development (R&D) at AbbVie.
  • "On behalf of the entire management team at 3T Biosciences, I am thrilled to welcome John to our board of directors," said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences.
  • "I believe in the company's mission and science, and I'm thrilled to join 3T's board of directors."
  • 3T Biosciences' 3T-TRACE platform technology is designed to overcome the challenges of advancing T-cell receptor (TCR)-based therapeutics.

Recent Fluvoxamine COVID benefits discovered using Cytel-designed platform trial

Retrieved on: 
Monday, September 13, 2021
Health, Infectious Diseases, Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology

There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.

Key Points: 
  • There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.
  • Platform trials, such as those used to test fluvoxamine, allow multiple therapies to be tested using a single study design with a shared control arm.
  • Dr. Wathen is well known for his work in platform trials having helped design several platform trials previously and his contributions and help in designing the I-SPY 2 trial, a platform trial that transformed breast cancer research.
  • The TOGETHER TRIAL may also open the door for platform trials to become a much more widespread research study design.

Kaletra - API Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 30, 2019
Health, AIDS, Infectious diseases, Pharmaceutical, Fixed dose combination, Hepatotoxins, Lopinavir/ritonavir, RTT, Application programming interface, Web API, Articles, Technology

The "Kaletra - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Kaletra - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Kaletra - API Insight, 2019 provides product and API manufacturers' details across the globe along with the location.
  • The report gives the clear idea on the country wise DMF filed by worldwide companies related to Kaletra.
  • The report also highlights the patent details of Kaletra.